#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13922	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2498	686.1	0	.	n	.	0	A69G	SNP	69	69	A	513	513	G	901	G,A,C	661,236,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13922	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2498	686.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1894	1894	T	871	T,A,G,C	867,2,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13922	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2498	686.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1628	1628	C	871	C	871	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23102	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3990	720.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1859	1859	A	924	A	924	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23102	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3990	720.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2493	2493	C	784	C,A	783,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23102	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3990	720.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2567	2567	A	710	A,G	709,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23102	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3990	720.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3119	3119	C	830	C,T,A	828,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2084	folP	852	852	99.88	folP.l15.c4.ctg.1	2107	123.1	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1091	1093	AAA	212;209;206	A;A,T,G;A,G	212;207,1,1;205,1	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2084	folP	852	852	99.88	folP.l15.c4.ctg.1	2107	123.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1322	1324	AGC	211;210;210	A;G;C,T	211;210;209,1	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4890	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	4048	150.7	1	SNP	p	S91F	0	.	.	271	273	TCC	880	882	TCC	185;185;184	T;C;C	185;185;184	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4890	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	4048	150.7	1	SNP	p	D95N	0	.	.	283	285	GAC	892	894	GAC	191;192;192	G,A;A;C	190,1;192;192	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4890	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	4048	150.7	1	SNP	p	D95G	0	.	.	283	285	GAC	892	894	GAC	191;192;192	G,A;A;C	190,1;192;192	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1828	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1830	124.6	1	SNP	p	G45D	0	.	.	133	135	GGC	697	699	GGC	185;184;181	G;G;C	185;184;181	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1020	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1641	77.6	0	.	n	.	0	A197.	DEL	197	197	A	899	899	A	184	A	184	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4548	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3491	162.4	1	SNP	p	D86N	0	.	.	256	258	GAC	823	825	GAC	205;205;203	G;A,G,C;C	205;203,1,1;203	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4548	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3491	162.4	1	SNP	p	S87I	0	.	.	259	261	AGT	826	828	AGT	202;207;206	A,G;G;T	201,1;207;206	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4548	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3491	162.4	1	SNP	p	S87W	0	.	.	259	261	AGT	826	828	AGT	202;207;206	A,G;G;T	201,1;207;206	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4548	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3491	162.4	1	SNP	p	S87R	0	.	.	259	261	AGT	826	828	AGT	202;207;206	A,G;G;T	201,1;207;206	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4548	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3491	162.4	1	SNP	p	S88P	0	.	.	262	264	TCC	829	831	TCC	210;210;212	T;C;C	210;210;212	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3952	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3173	155.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1837	1839	GGC	210;209;209	G;G;C	210;209;209	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1554	1556	GCA	207;207;204	G;C;A,C	207;207;203,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1557	1559	ATC	205;203;203	A,C;T;C	204,1;203;203	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1569	1571	GTG	203;205;208	G;T,C;G,T	203;204,1;207,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1569	1571	GTG	203;205;208	G;T,C;G,T	203;204,1;207,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2073	2075	ACC	217;216;214	A;C,G;C	217;215,1;214	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2127	2129	GCG	226;224;227	G;C,G;G	226;223,1;227	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2127	2129	GCG	226;224;227	G;C,G;G	226;223,1;227	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2250	2252	GGC	191;191;192	G,T,A;G;C	189,1,1;191;192	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2259	2261	GGC	197;197;199	G;G,T;C	197;196,1;199	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2877	161.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2277	2279	CTG	211;213;216	C;T;G,A	211;213;215,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5328	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3579	185.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1905	1907	CCG	203;205;205	C;C,T;G,C	203;204,1;204,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2394	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2423	123.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	903	903	C	190	C	190	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	20	22	TTA	19;21;21	T,G;T;A	18,1;21;21	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	65	67	CAT	54;54;54	C;A;T	54;54;54	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	68	70	AGT	54;54;54	A;G;T	54;54;54	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	77	79	TAC	54;54;54	T;A;C	54;54;54	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	R307A	NONSYN	919	921	AGA	167	169	GCA	2;2;2	G,A;C,G;A	1,1;1,1;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	179	181	GCA	2;2;2	G,A;C;A	1,1;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	182	184	GAC	2;2;2	G;A;C,A	2;2;1,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	188	190	ATC	2;2;3	A,T;T;C	1,1;2;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	194	196	TCG	4;4;4	T,G;C;G	3,1;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	200	202	GCC	4;4;4	G;C,T;C	4;3,1;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	203	205	AGC	4;4;4	A,G;G;C	3,1;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	206	208	GCC	4;4;4	G;C,G;C,T	4;3,1;3,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	232	90.52	porB1a.l15.c17.ctg.1	318	28.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	212	214	GTT	4;4;5	G;T,G;T	4;3,1;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	182	42.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	55;51;48	A;C;G	55;51;48	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	266	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	182	42.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	18;16;13	C;A;A	18;16;13	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	576	578	GAA	242;236;235	G;A;A	242;235;235	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	864	866	GAT	230;230;225	G,T;A;T	228,2;230;225	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	987	989	TCA	236;236;234	T;C;A,C	236;236;233,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	0	.	p	.	0	K207E	NONSYN	619	621	AAA	1083	1085	GAA	201;202;203	G,T,A;A;A	199,1,1;202;203	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	0	.	p	.	0	A218I	NONSYN	652	654	GCC	1116	1118	ATC	224;223;225	A,G;T,G;C,A	223,1;221,2;224,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1128	1130	TCT	234;235;233	T;C;T	234;235;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1446	1448	GCA	242;240;242	G;C;A,C	242;240;241,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	1	SNP	p	G120K	1	.	.	358	360	AAG	822	824	AAG	234;234;235	A,T;A;G	233,1;234;235	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	1	SNP	p	A121D	1	.	.	361	363	GAC	825	827	GAC	232;233;233	G,C;A,T;C	231,1;232,1;233	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2814	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1795	193.8	1	SNP	p	D121N	0	.	.	361	363	GAC	825	827	GAC	232;233;233	G,C;A,T;C	231,1;232,1;233	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9396	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5388	217.6	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2282	2284	AAT	226;225;229	A,C;A;T,C	223,2;225;228,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1398	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1507	115.4	1	SNP	p	V57M	1	.	.	169	171	ATG	738	740	ATG	232;230;230	A,C;T;G	231,1;230;230	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
